Treatment-resistant patients with focal epilepsy of unknown cause display reduced neurogranin levels: a preliminary study
Ideggyógyászati szemle · 2025
DOI: 10.18071/isz.78.0163 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ideggyógyászati szemle, 2025. Verfasst von Aysel Büşra Şişman und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Haseki Research and Training Hospital, Health Sciences University, Istanbul, Turkey. Hauptthemen laut MEDLINE: Neurogranin, Epilepsies, Partial, Drug Resistant Epilepsy.
Abstract (Originalsprache)
Background and purpose – The role of synaptic dysfunction in focal epilepsy of unknown cause is not well understood. Neurogranin is a post-synaptic protein used as a biomarker of synaptic disintegration in patients with dementia. Methods – To evaluate the association between synaptic loss, cognitive impairment and seizure activity in epilepsy, we collected sera of 51 patients with focal epilepsy of unknown cause, 26 with frontal lobe epilepsy (FLE) and 25 with mesial temporal lobe epilepsy with hippocampal sclerosis (MTLEHS), and 25 healthy controls. Serum neurogranin levels were measured by ELISA and we sought for potential correlations between neurogranin levels versus clinical features, cognitive test and quality of life scores of the patients. Results – Neurogranin levels were significantly reduced in MTLE-HS patients as compared to FLE patients and healthy controls but were not correlated with any of the clinical and cognitive variables. Both FLE and MTLE-HS patients with treatment resistance showed significantly reduced neurogranin levels. Conclusion – Our results suggest that MTLE-HS patients suffer from reduced synaptic protein production rather than increased synaptic breakdown. Reduction of neurogranin is associated with resistance to anti-epileptic treatment implying the role of this protein in the control of seizures. Neurogranin might serve as a biomarker for monitorization of seizure activity in focal epilepsies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Haseki Research and Training Hospital, Health Sciences University, Istanbul, Turkey.
- Istanbul Atlas University, Faculty of Health Sciences, Department of Speech and Language Therapy, Istanbul, Turkey.
- Department of Neuroscience, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.
- Department of Neurology, Gaziosmanpasa Research and Training Hospital, Health Sciences University, Istanbul, Turkey.
- Department of Biochemistry, Haseki Research and Training Hospital, Health Sciences University, Istanbul, Turkey.
ORCID-Profile: Aysel Büşra Şişman, Muhammet Duran Bayar, Aytül Mutlu, Vuslat Yilmaz, Erdem Tüzün
Zitieren
APA
Şişman, A. B., Savaş, M., Koral, G., Bayar, M. D., Yildiz, O., Mutlu, A., Yilmaz, V., Tüzün, E., & Cokar, Ö. (2025). Treatment-resistant patients with focal epilepsy of unknown cause display reduced neurogranin levels: a preliminary study. Ideggyógyászati szemle. https://doi.org/10.18071/isz.78.0163
Vancouver
Şişman AB, Savaş M, Koral G, Bayar MD, Yildiz O, Mutlu A, et al. Treatment-resistant patients with focal epilepsy of unknown cause display reduced neurogranin levels: a preliminary study. Ideggyógyászati szemle. 2025. doi:10.18071/isz.78.0163
BibTeX
@article{iman2025,
author = {Şişman, Aysel Büşra and Savaş, Merve and Koral, Gizem and Bayar, Muhammet Duran and Yildiz, Oğuz and Mutlu, Aytül and Yilmaz, Vuslat and Tüzün, Erdem and Cokar, Özlem},
title = {Treatment-resistant patients with focal epilepsy of unknown cause display reduced neurogranin levels: a preliminary study},
journal = {Ideggyógyászati szemle},
year = {2025},
doi = {10.18071/isz.78.0163}
}
EUVIMED